Thermo Fisher Scientific Inc. (TMO) Director Tyler Jacks Sells 4,772 Shares
Thermo Fisher Scientific Inc. (NYSE:TMO) Director Tyler Jacks sold 4,772 shares of Thermo Fisher Scientific stock in a transaction dated Monday, November 19th. The stock was sold at an average price of $239.75, for a total value of $1,144,087.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of Thermo Fisher Scientific stock opened at $233.40 on Wednesday. The company has a quick ratio of 1.27, a current ratio of 1.84 and a debt-to-equity ratio of 0.66. Thermo Fisher Scientific Inc. has a twelve month low of $181.51 and a twelve month high of $249.95. The stock has a market capitalization of $93.75 billion, a P/E ratio of 24.59, a price-to-earnings-growth ratio of 1.69 and a beta of 1.08.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 24th. The medical research company reported $2.62 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.55 by $0.07. Thermo Fisher Scientific had a return on equity of 16.49% and a net margin of 10.75%. The firm had revenue of $5.92 billion during the quarter, compared to analyst estimates of $5.70 billion. During the same quarter in the previous year, the business earned $2.31 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 15.7% compared to the same quarter last year. Analysts forecast that Thermo Fisher Scientific Inc. will post 11.04 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, January 15th. Investors of record on Monday, December 17th will be paid a $0.17 dividend. The ex-dividend date of this dividend is Friday, December 14th. This represents a $0.68 annualized dividend and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio is presently 7.17%.
A number of hedge funds have recently bought and sold shares of the stock. Pitcairn Co. boosted its holdings in Thermo Fisher Scientific by 1.3% in the 2nd quarter. Pitcairn Co. now owns 16,871 shares of the medical research company’s stock worth $3,495,000 after buying an additional 215 shares during the last quarter. Hall Capital Management Co. Inc. boosted its holdings in Thermo Fisher Scientific by 6.2% in the 3rd quarter. Hall Capital Management Co. Inc. now owns 3,780 shares of the medical research company’s stock worth $923,000 after buying an additional 220 shares during the last quarter. Nvwm LLC boosted its holdings in Thermo Fisher Scientific by 6.1% in the 2nd quarter. Nvwm LLC now owns 4,231 shares of the medical research company’s stock worth $877,000 after buying an additional 242 shares during the last quarter. Tiedemann Advisors LLC boosted its holdings in Thermo Fisher Scientific by 19.4% in the 2nd quarter. Tiedemann Advisors LLC now owns 1,518 shares of the medical research company’s stock worth $315,000 after buying an additional 247 shares during the last quarter. Finally, Chesapeake Wealth Management boosted its holdings in Thermo Fisher Scientific by 6.0% in the 2nd quarter. Chesapeake Wealth Management now owns 4,393 shares of the medical research company’s stock worth $910,000 after buying an additional 249 shares during the last quarter. Institutional investors own 85.47% of the company’s stock.
A number of research firms have weighed in on TMO. UBS Group began coverage on Thermo Fisher Scientific in a research note on Tuesday, October 9th. They set a “buy” rating and a $295.00 price objective for the company. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $274.00 price objective for the company in a research note on Monday, October 1st. Goldman Sachs Group lowered Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research note on Monday, September 17th. Morgan Stanley lifted their price objective on Thermo Fisher Scientific from $242.00 to $254.00 and gave the company an “overweight” rating in a research note on Wednesday, October 10th. Finally, Cleveland Research lowered Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research note on Thursday, October 18th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $263.55.
ILLEGAL ACTIVITY NOTICE: “Thermo Fisher Scientific Inc. (TMO) Director Tyler Jacks Sells 4,772 Shares” was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2018/11/21/thermo-fisher-scientific-inc-tmo-director-tyler-jacks-sells-4772-shares.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Read More: Asset Allocation
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.